Hudson Bay Capital Management
REGN icon

Hudson Bay Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hudson Bay Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,100
Closed -$1.97M – 1612
2025
Q1 		$1.97M Buy
+3,100
New +$2.13M 0.01% 825

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hudson Bay Capital Management's REGN Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, buying an estimated $4.5M and bringing the position to 32,001 shares worth $24.7M. The position accounts for 0.09% of the portfolio, ranked #169.

Hudson Bay Capital Management first reported a position in REGN in Q1 2018 and has held it in 19 quarters since. The position peaked at $36.4M in Q4 2023. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Hudson Bay Capital Management held 32,001 shares of Regeneron Pharmaceuticals worth $24.7M as of Q1 2026.
  • Hudson Bay Capital Management bought 5,874 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.5M.
  • Regeneron Pharmaceuticals made up 0.09% of Hudson Bay Capital Management's portfolio in Q1 2026, its #169 holding.
  • Hudson Bay Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 19 quarters since.
  • Hudson Bay Capital Management's Regeneron Pharmaceuticals position peaked at $36.4M in Q4 2023.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.